Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial COVID-19 vaccine Novavax became the first to demonstrate clinical efficacy against both UK and South Africa Covid-19 strains, as was reported by the Novavax company press-release.
